Dapk3 Antibody

What is DAPK3 and what are its primary biological functions?

DAPK3 (also known as ZIPK or DLK) belongs to the protein kinase superfamily, specifically the CAMK Ser/Thr protein kinase family and DAP kinase subfamily. It functions as:

• A positive regulator of apoptosis

• A kinase that phosphorylates histone H3 on threonine-11 at centromeres during mitosis

• A regulator of myosin light chain phosphatase through MYPT1 phosphorylation

• An essential component for STING activation driving tumor-intrinsic innate immunity

• A participant in mRNA processing of immediate early genes

DAPK3 has been implicated in multiple cellular processes including cell cycle regulation, cytokinesis, and immune response pathways .

What are the standard applications for DAPK3 antibodies in research?

DAPK3 antibodies have been validated for multiple applications:

When selecting an antibody, researchers should verify species reactivity, which commonly includes human, mouse, and rat samples .

How do researchers distinguish between different isoforms of DAPK3?

DAPK3 can be detected at two primary molecular weights:

• 52-53 kDa: Full-length protein, the calculated molecular weight

• 37 kDa: Shorter isoform recognized by some antibodies

To distinguish between these isoforms:

• Use appropriate gel percentages (12% SDS-PAGE is commonly effective)

• Include positive controls with known expression patterns

• Apply longer separation times during electrophoresis

• Consider using antibodies that specifically recognize each isoform or epitopes unique to the full-length protein

This distinction is particularly important when studying functional differences between DAPK3 variants in different cellular contexts .

How can DAPK3 antibodies be used to investigate its role in tumor immunity?

Recent research has identified DAPK3 as an essential kinase for STING activation that drives tumor-intrinsic immunity. Methodological approaches include:

• Tumor microenvironment analysis: Use DAPK3 antibodies to assess expression in tumor cells versus infiltrating immune cells through IHC or IF

• Immune cell infiltration studies: Combine DAPK3 staining with markers for:

  • CD103+CD8α+ dendritic cells

  • NK cells

  • CD8+ T cells

  • Regulatory T cells

  • M2 macrophages

• Mechanistic analysis: Use co-immunoprecipitation with DAPK3 antibodies to identify:

  • STING interactions (particularly K48 and K63-linked poly-ubiquitination)

  • TBK1 complex formation

  • Regulation of post-translational modifications

• Knockout/knockdown validation: Compare antibody staining patterns in DAPK3-depleted versus control cells to establish specificity

In MCA205 and B16F10 tumor models, DAPK3 depletion accelerated tumor growth in vivo despite inhibitory effects on proliferation in vitro, highlighting the importance of context-specific analysis .

What controls should be used when validating DAPK3 antibody specificity?

Proper antibody validation requires multiple controls:

• Positive controls:

  • Cell lines with known DAPK3 expression (A431, HEK-293, HeLa, and HepG2 cells have been confirmed)

  • Recombinant DAPK3 protein (useful as loading control)

• Negative controls:

  • DAPK3 knockout/knockdown samples generated via CRISPR/Cas9 or shRNA

  • Peptide competition assays to demonstrate binding specificity

  • Secondary antibody-only controls to assess non-specific binding

• Specificity controls:

  • Parallel testing with antibodies targeting different DAPK3 epitopes

  • Cross-reactivity assessment with other DAPK family members (DAPK1, DAPK2)

  • Testing of cancer-associated mutant variants (T112M, D161N, P216S)

How should researchers investigate DAPK3 mutations when studying cancer samples?

Cancer-associated loss-of-function mutations in DAPK3 have significant implications for research:

• Mutation screening approach:

  • PCR amplification and sequencing of DAPK3 from tumor samples

  • Specific attention to mutations T112M, D161N, and P216S which are predicted to be cancer-associated by algorithms like CanPredict and PMUT

• Functional validation methods:

  • Kinase activity assays using immunoprecipitated FLAG-DAPK3 with GST-tagged myosin light chain as substrate

  • BrdU incorporation assays to assess effects on cell proliferation

  • Cell cycle analysis to determine G1/S ratios

  • Assessment of cellular aggregation phenotypes

  • Chemotherapy sensitivity testing

• Dominant-negative assessment:

  • Co-expression of wild-type and mutant DAPK3 to detect suppression of wild-type function

  • Controls using catalytically inactive DAPK3 mutants (e.g., T180A) for comparison

These cancer-related mutations decrease or abolish kinase function and can act in a dominant-negative fashion, making accurate detection crucial for interpreting results .

What methodology should be used when studying DAPK3's role in histone phosphorylation?

DAPK3 phosphorylates histone H3 on threonines 6 and 11, which correlates with transcriptional activation of immediate early genes. To investigate this function:

• Chromatin immunoprecipitation (ChIP):

  • Use antibodies against phosphorylated H3T6 and H3T11 to identify DAPK3-regulated genes

  • Perform sequential ChIP with DAPK3 antibodies followed by H3 phosphorylation antibodies

• RNA polymerase II interaction studies:

  • Co-immunoprecipitate DAPK3 with RNA polymerase II antibodies

  • Analyze recruitment patterns following cellular stimulation (e.g., anti-IgM treatment in B cells)

• Transcriptional analysis:

  • Correlate histone phosphorylation with expression of immediate early genes like EGR1 and DUSP2

  • Compare effects of DAPK inhibitors versus BTK inhibitors (e.g., ibrutinib)

• Kinase activity assays:

  • In vitro kinase assays using recombinant H3 as substrate

  • Assess effects of specific inhibitors on H3T6 and H3T11 phosphorylation

This approach has been particularly informative in chronic lymphocytic leukemia (CLL) studies where DAPK3 mediates histone modifications in response to B-cell receptor signaling .

What sample preparation protocols optimize DAPK3 detection in different applications?

For optimal DAPK3 detection across various applications:

Western Blotting:

• Lyse cells in buffer containing: 20 mM HEPES (pH 7.4), 1% Triton X-100, 1 mM DTT, 200 μM benzamidine, 40 μg/ml leupeptin, and 1 mM PMSF

• Brief sonication (3 seconds) improves protein extraction

• Preclearing lysates reduces background

• Use 12% SDS-PAGE gels for optimal separation

• For small tissue samples (like cerebral arterioles), use specialized buffers containing 60 mM Tris-HCl (pH 6.8), 4% SDS, 10 mM DTT, 10% glycerol

Immunoprecipitation:

• For FLAG-tagged DAPK3, incubate detergent-soluble lysates overnight at 4°C with FLAG antibody and Protein A/G beads

• For endogenous DAPK3, use specific DAPK3 antibodies with longer incubation periods (16+ hours at 4°C)

• Include phosphatase inhibitors when studying phosphorylation-dependent interactions

Immunohistochemistry:

• Deparaffinize tissues and rehydrate with gradient ethanol

• Perform heat-induced antigen retrieval in 10 mM sodium citrate (pH 6.0)

• Block with 10% normal donkey serum in PBS

• Incubate overnight at 4°C with anti-DAPK3 antibody (1:400 dilution)

• Use appropriate secondary antibodies (e.g., Cy3-conjugated AffiniPure donkey anti-rabbit IgG at 1:200)

How can phosphorylated forms of DAPK3 be effectively detected?

Detecting phosphorylated DAPK3 requires specialized approaches:

• Phos-Tag SDS-PAGE:

  • Incorporate Phos-Tag-acrylamide into standard SDS-PAGE gels

  • This technique retards migration of phosphorylated proteins, creating distinct bands

  • Can be used to monitor DAPK3 phosphorylation states without phospho-specific antibodies

• Phospho-proteomics approaches:

  • Tandem mass tag (TMT)-labeling-based mass spectrometry can identify DAPK3 phosphorylation sites

  • This technique identified that DAPK3 phosphorylates targets at the consensus sequence R/K-X-X-S/T

• When analyzing DAPK3's kinase activity:

  • Investigate phosphorylation of known substrates (myosin light chain, LMO7)

  • Focus on the DAPK3-specific phosphosite on the E3 ligase LMO7, critical for LMO7-STING interaction

• Sample handling considerations:

  • Rapid sample processing is essential to preserve phosphorylation states

  • Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate) in all buffers

  • Avoid multiple freeze-thaw cycles of samples

What are the optimal conditions for using DAPK3 antibodies in co-immunoprecipitation studies?

For successful co-immunoprecipitation of DAPK3 and interacting partners:

• Buffer composition:

  • Use binding buffer containing physiological salt concentrations (~150 mM NaCl)

  • Include 0.1-1% non-ionic detergent (Triton X-100 or NP-40)

  • Add protease inhibitors and phosphatase inhibitors to preserve interactions

• Quantification approach:

  • Quantify immunoprecipitated proteins by comparing Coomassie blue staining to standards

  • For direct binding assays, use 100 ng of purified proteins (e.g., TAP-DANGER incubated with GST-DAPK3)

  • Add beads (e.g., glutathione-Sepharose for GST-tagged proteins) for 30 minutes

• Washing conditions:

  • Perform at least three washes with binding buffer

  • Balance between removing non-specific interactions and preserving specific ones

  • For weaker interactions, reduce salt concentration during washes

• Controls to include:

  • IgG control immunoprecipitations

  • Reciprocal co-IPs (pull down with antibody against interacting protein)

  • Mutant forms of DAPK3 (kinase-dead versions) to determine if interactions are activity-dependent

These approaches have successfully demonstrated interactions between DAPK3 and proteins like DANGER, TBK1, and STING .

How can DAPK3 antibodies be used to investigate its role in cancer immunotherapy response?

DAPK3's role in tumor-intrinsic immunity makes it relevant for immunotherapy research:

Research has shown that DAPK3-depleted tumors showed accelerated growth in vivo but not in vitro, suggesting important tumor-immune interaction effects that could influence immunotherapy response .

What methods should be used to analyze DAPK3's role in chronic lymphocytic leukemia (CLL)?

DAPK3 participates in mRNA processing of immediate early genes in CLL, requiring specialized methodological approaches:

• B-cell receptor (BCR) signaling analysis:

  • Stimulate CLL cells with anti-IgM to activate BCR signaling pathway

  • Monitor histone H3 threonine 6 and 11 phosphorylation by Western blotting

  • Compare to effects of inhibitors (ibrutinib vs. DAPK inhibitors)

• RNA processing investigation:

  • Focus on immediate early genes like EGR1 and DUSP2

  • Distinguish between transcriptional activation and mRNA processing effects

  • Analyze effects of DAPK inhibition on both anti-IgM and CD40L-dependent activation

• Proliferation assays:

  • Compare anti-proliferative effects of DAPK inhibitors versus BTK inhibitors

  • Assess CLL cell viability under various stimulation conditions

• Mechanistic studies:

  • Evaluate DAPK3 recruitment to RNA polymerase II in an anti-IgM-dependent manner

  • Analyze whether DAPK3 inhibition impacts transcription itself or affects post-transcriptional processes

These approaches revealed that DAPK inhibition mimics ibrutinib-induced repression of both immediate early gene mRNA and histone H3 phosphorylation but has a broader anti-tumor effect by repressing both anti-IgM- and CD40L-dependent activation .

How should researchers interpret contradictory data between in vitro and in vivo effects of DAPK3?

Several studies have shown apparent contradictions between DAPK3's effects in different contexts:

• Systematic approach to resolve contradictions:

  • Document experimental conditions precisely (cell type, expression level, stimulus)

  • Consider temporal dynamics of DAPK3 activity using time-course experiments

  • Distinguish between direct (kinase-dependent) and scaffolding functions

  • Evaluate context-specific post-translational modifications

• Specific case study methodology:

  • In MCA205 and B16F10 cancer models, DAPK3 depletion impaired in vitro proliferation but accelerated in vivo tumor growth

  • Analysis revealed this contradiction stemmed from DAPK3's dual roles:

    • Cell-intrinsic regulation of cytokinesis

    • Immune-modulatory effects via STING pathway activation

• Investigative framework:

  • Compare effects in immunocompetent versus immunodeficient models

  • Use conditional knockout approaches for tissue-specific analysis

  • Employ rescue experiments with wild-type versus mutant DAPK3

  • Consider microenvironmental factors that may be absent in vitro

• Data integration approach:

  • Create comprehensive datasets across multiple experimental systems

  • Document protein interaction networks in different cellular contexts

  • Consider compensatory mechanisms that may operate in vivo but not in vitro

This analytical approach helps resolve the seeming contradiction that DAPK3 loss can simultaneously impair cellular proliferation while promoting tumor growth through immune evasion mechanisms .

How can phospho-proteomic approaches be combined with DAPK3 antibodies for target identification?

Advanced phospho-proteomic studies have revealed DAPK3's substrate network:

• Integrated workflow:

  • Perform tandem mass tag (TMT)-labeling-based mass spectrometry on:

    • Control samples

    • DAPK3-depleted samples (shDAPK3)

    • TBK1-depleted samples (shTBK1) for comparison

• Prioritization strategy:

  • Identify phospho-proteins showing hypo-phosphorylation in shRNA-treated lysates

  • Focus on 196 phospho-sites in 165 proteins demonstrating hypo-phosphorylation at DAPK3 consensus sequence (R/K-X-X-S/T)

  • Compare with proteins hypo-phosphorylated at the IKK consensus sequence (S-X-X-X-S/T)

• Pathway analysis approach:

  • Use Ingenuity Pathway Analysis (IPA) of DAPK3-specific clusters

  • Identify enrichment of key regulatory kinases (ERK/MAPK, mTOR, SAPK/JNK)

  • Focus on innate immune response genes specific for cytokine and IRF signaling

  • Note connections to Rho signaling, actin remodeling, and autophagy pathways

• Validation strategy:

  • Confirm interactions using co-immunoprecipitation

  • Verify subcellular localization with confocal microscopy

  • Conduct in vitro kinase assays with purified components

This methodology identified LMO7 as a DAPK3 substrate, with a DAPK3-specific phosphosite critical for LMO7-STING interaction and STING K63-linked poly-ubiquitination .

What approaches should be used to study the DAPK family interactions using antibodies?

Studying interactions between DAPK family members requires specialized approaches:

• Comparative immunoprecipitation:

  • Use antibodies against different DAPK family members (DAPK1, DAPK2/DRP-1, DAPK3/ZIPK)

  • Perform reciprocal co-immunoprecipitations to verify interactions

  • Include domain-specific antibodies to map interaction regions

• Cross-reactivity control strategy:

  • Due to high homology in catalytic domains, verify antibody specificity against each family member

  • Include recombinant proteins as controls

  • Use cells with genetic deletion of specific family members as negative controls

• Functional domain analysis:

  • Compare interactions with:

    • Full-length DAPK3

    • Catalytic domain only

    • Kinase-dead mutants (T180A)

    • Truncation mutants (Δ273)

    • Cancer-associated mutants (T112M, D161N, P216S)

• Cross-regulation assessment:

  • Investigate if DAPK family members phosphorylate each other

  • Determine if they compete for common binding partners

  • Analyze if they form multiprotein complexes

Research has shown DANGER protein interacts with multiple DAPK family members, including DAPK1, DAPK2, and DAPK3, suggesting potential functional overlap or coordination between these kinases .

What methodological considerations apply when using DAPK3 antibodies in tissue-specific research?

DAPK3 functions in a tissue-specific manner, requiring tailored approaches:

• Cerebral arteriole studies:

  • For protein extraction from small vessels:

    • Collect tissues in SDS-PAGE Sample Buffer containing 60 mM Tris-HCl (pH 6.8), 4% SDS, 10 mM DTT, 10% glycerol

    • Vortex for 16 hours at 4°C for complete extraction

    • Heat samples to 95°C for 10 minutes before storage

  • Use 12% SDS-PAGE gels for optimal separation

  • Include αSM-actin and LC20 as vascular smooth muscle markers

• Intestinal tissue analysis:

  • For immunohistochemistry:

    • Perform heat-induced antigen retrieval in 10 mM sodium citrate (pH 6.0)

    • Block with 10% normal donkey serum

    • Incubate with anti-DAPK3 at 1:400 dilution overnight at 4°C

    • Co-stain with proliferation markers (Ki-67) to assess correlation

    • Use DAPI (10 μg/mL) to mark nuclei

• Cancer tissue microarrays:

  • Compare DAPK3 expression across multiple tumor types

  • Correlate with clinical parameters and survival data

  • Analyze subcellular localization patterns (nuclear vs. cytoplasmic)

• Cross-species considerations:

  • Verify antibody reactivity across species (human, mouse, rat)

  • Confirm applicability to both normal and pathological tissues

  • Consider fixation-dependent epitope masking effects

These approaches have been successfully applied to study DAPK3's role in myogenic response of cerebral arterioles and intestinal function .